The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Spotlight Series: HIV Stigma and Discrimination
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

International News

Research Roundup: Use of Generic Drugs Reduces Costs of AIDS Relief

July 13, 2012

Since its inception nearly a decade ago, a US program for supplying AIDS medications to the developing world has grown significantly. Meanwhile, costs of treatment per patient have dramatically fallen. The primary reason? The increasing availability of generic antiretroviral drugs, according to a review article published in the July issue of Health Affairs. The President's Emergency Plan for AIDS Relief (PEPFAR) was set up in 2003 with the aim of supporting prevention, treatment, and care efforts in 15 focus countries in the developing world (Fox, Medscape, 7/9).

Back to other news for July 2012

This article was reprinted from with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily Health Policy Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.
See Also
More on Generic/Discount HIV Drug Access in the Developing World

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining: